Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes-Reference-Cited by-同舟云学术

Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes

Published:2014-12-22 Issue:3 Volume:17 Page:254-260
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Shiramoto M.¹,Eto T.¹,Irie S.¹,Fukuzaki A.²,Teichert L.³,Tillner J.³,Takahashi Y.²,Koyama M.²,Dahmen R.³,Heise T.⁴,Becker R. H. A.³

Affiliation:

1. Hakata Clinic, LTA Clinical Pharmacology Center Fukuoka Japan

2. Sanofi Tokyo Japan

3. Sanofi‐Aventis Deutschland GmbH Frankfurt am Main Germany

4. Profil Neuss Germany

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12415

Reference15 articles.

1. Use of Insulin Glargine in Japanese Patients with Type 1 Diabetes

2. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

3. New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes;Jax T;Diabetologia,2013

4. Euglycaemic single dose clamp profile of new insulin glargine formulation in subjects with type 1 diabetes is flat and prolonged;Tillner J;Diabetologia,2013

5. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus;Expert Review of Endocrinology & Metabolism;2024-02-20

2. Therapy for Type 1 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-02-16

3. Therapie des Typ-1-Diabetes – Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057-013; 4. Auflage 2018);Diabetologie und Stoffwechsel;2023-10

4. Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study;Diabetes Therapy;2023-06-17

5. Treatment of type 1 diabetes;Die Diabetologie;2023-05-08